30Jan 2021
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors

Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors

Several immune checkpoint inhibitors (ICIs) are FDA approved for treatment of genitourinary (GU) malignancies. We aim to determine demographic and clinicopathologic characteristics that significantly affect clinical outcomes in patients with advanced stage GU malignancies treated with ICIs.

  • #urology

Like

Save

Share